Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy
July 14, 2026
VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies
3 min read
False
Advertisement
Industry News
FDA Selects Seven Companies for Drug Manufacturing Pilot
July 13, 2026
Selected companies will receive earlier FDA engagement to support new US drug manufacturing facilities across small molecules, biologics, sterile injectables, and advanced therapies
2 min read
Fujifilm and HORIBA Develop Inline Raman System for Biomanufacturing
June 29, 2026
The system is designed for real-time monitoring of cell culture and purification, with Fujifilm reporting about a 10 percent yield improvement in antibody purification tests
2 min read
Parabilis Sets Biotech IPO Record
June 15, 2026
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
1 min read
This Week’s Biopharma News: Big Moves in Bispecifics
June 9, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
4 min read
This Week’s CGT News: Promising Data for In Vivo CAR T
June 8, 2026
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
5 min read
This Week’s Biopharma News: New Approvals, Appeals, and AI
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
This Week’s CGT News: Base Editing Takes Aim at Cholesterol
June 1, 2026
Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M
3 min read
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
